Archives
Parathyroid hormone (1-34) (human): Mechanistic Foundatio...
Parathyroid hormone (1-34) (human): Mechanistic Foundation for Bone and Kidney Research
Executive Summary: Parathyroid hormone (1-34) (human) is a synthetic peptide representing the active N-terminal fragment of human parathyroid hormone, precisely 34 amino acids in length and with a molecular weight of 4117.72 Da (APExBIO). This peptide is a high-affinity agonist for both PTH1R and PTH2R, stimulating cAMP production in vitro at an IC50 of 0.22 nM in HEK293 cells (APExBIO). It robustly regulates serum calcium by acting on bone, kidney, and intestinal tissues (Huang et al., 2025). Dose-dependent increases in bone mass have been demonstrated in vivo in Fisher 344 rats with subcutaneous administration at 10–40 μg/kg/day (APExBIO). The peptide is highly water- and DMSO-soluble, making it compatible with a range of experimental protocols (APExBIO).
Biological Rationale
Parathyroid hormone (1-34) (human) is a truncated, biologically active peptide derived from the full human parathyroid hormone. The first 34 amino acids retain full agonist activity at parathyroid hormone 1 and 2 receptors (PTH1R, PTH2R), which are expressed in bone, kidney, and intestinal tissues (APExBIO). The chief cells of the parathyroid glands produce endogenous PTH, which is central to systemic calcium and phosphate regulation (Huang et al., 2025). Experimental models employing PTH (1-34) enable precise modulation of these physiological pathways, underpinning translational research in bone remodeling, calcium homeostasis, and chronic kidney disease. The use of spatially patterned kidney assembloids further extends the utility of this peptide for modeling human disease with greater fidelity (Huang et al., 2025). For a deeper dive into mechanistic underpinnings and translational promise, see this detailed mechanistic article, which our present review extends by providing updated experimental benchmarks.
Mechanism of Action of Parathyroid hormone (1-34) (human)
PTH (1-34) binds to the PTH1R, a class B G protein-coupled receptor, with high affinity. This triggers the activation of adenylate cyclase, leading to elevated intracellular cAMP levels (IC50 = 0.22 nM in transfected HEK293 cells, 37°C, pH 7.4) (APExBIO). The cAMP signaling cascade activates protein kinase A (PKA), modulating downstream targets that control calcium and phosphate transport. PTH (1-34) also stimulates inositol phosphate synthesis, contributing to phospholipase C activation and intracellular calcium mobilization. These parallel pathways regulate:
- Bone resorption (mobilizing calcium from bone matrix)
- Renal reabsorption of calcium and magnesium (distal tubules, thick ascending limb)
- Upregulation of 1α-hydroxylase, increasing active vitamin D (calcitriol) synthesis in the kidney
- Enhanced intestinal calcium absorption via vitamin D–mediated mechanisms
Unlike the full-length hormone, PTH (1-34) lacks C-terminal residues responsible for some catabolic activities, making it a preferred research tool for dissecting anabolic bone responses. For extended mechanistic context, our review updates and clarifies the signaling analysis presented in previous articles by including latest receptor-specific benchmarks.
Evidence & Benchmarks
- PTH (1-34) stimulates cAMP production in PTH1R-transfected human kidney 293 cells with an IC50 of 0.22 nM (37°C, pH 7.4) (APExBIO).
- Subcutaneous administration in male Fisher 344 rats (10 or 40 μg/kg/day, 6 weeks) results in significant, dose-dependent increases in trabecular and cortical bone mass (APExBIO).
- Peptide is soluble at ≥399.3 mg/mL in DMSO and ≥19.88 mg/mL in water; insoluble in ethanol (25°C, neutral pH) (APExBIO).
- In spatially patterned kidney assembloids, PTH/PTHrP pathway activation recapitulates key aspects of nephron–collecting duct interactions, supporting advanced disease modeling (Huang et al., 2025).
- High-purity formulation (>97.8%) supports reproducibility and minimizes off-target effects in in vitro and in vivo assays (APExBIO).
This dataset extends the comparative performance analysis previously reported in Redefining Translational Research in Bone and Kidney Models by adding direct solubility and in vivo potency benchmarks.
Applications, Limits & Misconceptions
PTH (1-34) is widely used as a tool compound in bone metabolism research, osteoporosis models, and studies of calcium homeostasis regulation. Its role as a PTH1R agonist makes it central to experimental systems dissecting cAMP signaling and inositol phosphate synthesis. The peptide is also a key agent in recapitulating parathyroid hormone signaling in spatially patterned kidney assembloids for disease modeling, as demonstrated in advanced organoid platforms (Huang et al., 2025).
For further context on its operational limits and best practices, researchers are encouraged to consult this workflow-focused guide, which our current article expands by incorporating updated solubility and storage recommendations.
Common Pitfalls or Misconceptions
- Diagnostic/therapeutic use: PTH (1-34) (human) is not approved for human diagnostic or therapeutic applications; for research use only (APExBIO).
- Solvent compatibility: The peptide is insoluble in ethanol and may precipitate in high ionic strength buffers.
- Long-term solution stability: Reconstituted solutions should not be stored long-term; use freshly prepared aliquots to avoid degradation (APExBIO).
- Species specificity: While highly conserved, minor sequence variations may affect potency or receptor selectivity in non-human models.
- Overinterpretation of in vitro data: Cellular responses may not fully predict in vivo pharmacodynamics, especially in complex tissue environments.
Workflow Integration & Parameters
PTH (1-34) (human) is supplied as a solid, high-purity (>97.8%) peptide, intended for research use only (APExBIO). For dissolution, DMSO is preferred (≥399.3 mg/mL solubility), followed by water (≥19.88 mg/mL); avoid ethanol. Store the solid desiccated at -20°C. Prepare working aliquots fresh; avoid repeated freeze-thaw cycles. Typical cell-based assay concentrations range from 0.1 to 100 nM, with cAMP readouts over 15–60 minutes at 37°C. For in vivo studies, dosing regimens of 10–40 μg/kg/day subcutaneously in rodents are standard (APExBIO). Integration with advanced platforms such as kidney assembloids enables high-fidelity modeling of PTH/PTHrP signaling in renal epithelial–mesenchymal crosstalk (Huang et al., 2025).
Conclusion & Outlook
Parathyroid hormone (1-34) (human) from APExBIO is a rigorously defined, highly potent tool for dissecting parathyroid hormone signaling in bone and kidney research. Its quantitative benchmarks for receptor activation, solubility, and bone anabolic activity underpin reproducible experimental design for both in vitro and in vivo systems. The emergence of organoid and assembloid platforms, such as spatially patterned kidney assembloids, further amplifies its translational relevance (Huang et al., 2025). Adherence to best practices in solubilization, storage, and dosing is essential to maximize scientific rigor and reproducibility.
For authoritative sourcing, detailed protocols, and reagent specifications, refer to the product page for Parathyroid hormone (1-34) (human) (SKU A1129).